Castration-resistant prostate cancer: Descriptive yet pejorative?

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages

  Crawford, E David ^a   Petrylak, Daniel ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; TESTIS; MALE; NOMENCLATURE; NOTE; ORCHIECTOMY; PROSTATE TUMOR; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TERMINOLOGY AS TOPIC; TREATMENT FAILURE;

EID: 77957252670     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.7664     Document Type: Letter

References (4)

1. Ahman RF, Crawford ED, Kries W, et al: Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Cancer Res 47:4736-4739, 1987 (Pubitemid 17127426)
2. Scher Hi, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
3. Attard G, Alison HM, A'Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-373748, 2009
4. Tran C, Ouk S, Clegg NJ, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790, 2009